- Home
- MGRC vs NAMS Comparison
MGRC vs NAMS Comparison
Compare MGRC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRC
- NAMS
- Stock Information
- Founded
- MGRC 1979
- NAMS 2019
- Country
- MGRC United States
- NAMS Netherlands
- Employees
- MGRC N/A
- NAMS N/A
- Industry
- MGRC Diversified Commercial Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- MGRC Consumer Discretionary
- NAMS Health Care
- Exchange
- MGRC Nasdaq
- NAMS Nasdaq
- Market Cap
- MGRC 3.0B
- NAMS 2.7B
- IPO Year
- MGRC N/A
- NAMS N/A
- Fundamental
- Price
- MGRC $127.18
- NAMS $18.57
- Analyst Decision
- MGRC Buy
- NAMS Strong Buy
- Analyst Count
- MGRC 2
- NAMS 7
- Target Price
- MGRC $145.50
- NAMS $41.33
- AVG Volume (30 Days)
- MGRC 154.4K
- NAMS 646.5K
- Earning Date
- MGRC 02-19-2025
- NAMS 03-04-2025
- Dividend Yield
- MGRC 1.52%
- NAMS N/A
- EPS Growth
- MGRC 32.46
- NAMS N/A
- EPS
- MGRC 9.43
- NAMS N/A
- Revenue
- MGRC $910,942,000.00
- NAMS $33,594,000.00
- Revenue This Year
- MGRC $12.09
- NAMS $131.53
- Revenue Next Year
- MGRC $1.26
- NAMS N/A
- P/E Ratio
- MGRC $13.49
- NAMS N/A
- Revenue Growth
- MGRC 9.51
- NAMS 78.77
- 52 Week Low
- MGRC $95.50
- NAMS $15.19
- 52 Week High
- MGRC $129.93
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- MGRC 63.36
- NAMS 29.65
- Support Level
- MGRC $119.18
- NAMS $18.88
- Resistance Level
- MGRC $123.80
- NAMS $20.46
- Average True Range (ATR)
- MGRC 2.94
- NAMS 1.11
- MACD
- MGRC 0.34
- NAMS -0.09
- Stochastic Oscillator
- MGRC 74.42
- NAMS 5.84
About MGRC McGrath RentCorp
McGrath RentCorp is a rental company. It is comprised of four reportable business segments: Modular building and portable storage segment (Mobile Modular), Electronic test equipment segment (TRS-RenTelco), Containment solutions for the storage of hazardous and non-hazardous liquids and solids segment (Adler Tanks) and Classroom manufacturing division selling modular classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.